Cardiff Oncology, Inc. (CRDF)
Largest Insider Buys in Sector
CRDF Stock Price History Chart
CRDF Stock Performance
About Cardiff Oncology, Inc.
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for …
Insider Activity of Cardiff Oncology, Inc.
Over the last 12 months, insiders at Cardiff Oncology, Inc. have bought $1.01M and sold $0 worth of Cardiff Oncology, Inc. stock.
On average, over the past 5 years, insiders at Cardiff Oncology, Inc. have bought $590,238 and sold $657,020 worth of stock each year.
Highest buying activity among insiders over the last 12 months: PACE GARY W (director) — $3.76M. Levine James E. (Chief Financial Officer) — $73,451. TANNENBAUM RENEE P (director) — $68,448.
The last purchase of 2,400 shares for transaction amount of $12,000 was made by Levine James E. (Chief Financial Officer) on 2024‑12‑18.
List of Insider Buy and Sell Transactions, Cardiff Oncology, Inc.
| 2024-12-18 | Chief Financial Officer | 2,400 0.0041% | $5.00 | $12,000 | -7.70% | |||
| 2024-12-17 | Chief Financial Officer | 2,752 0.0053% | $5.42 | $14,905 | -22.15% | |||
| 2024-12-16 | Chief Financial Officer | 2,564 0.0048% | $3.83 | $9,820 | +5.71% | |||
| 2024-12-12 | director | 10,000 0.0209% | $3.42 | $34,224 | +24.46% | |||
| 2024-12-11 | director | 361,615 0.5003% | $2.60 | $940,199 | +9.46% | |||
| 2023-12-19 | director | 30,000 0.0671% | $1.37 | $41,100 | +89.78% | |||
| 2022-11-25 | Chief Executive Officer | 10,000 0.0236% | $1.43 | $14,300 | +14.39% | |||
| 2022-09-19 | director | 15,000 0.0327% | $1.64 | $24,525 | -7.51% | |||
| 2022-09-16 | Chief Financial Officer | 30,000 0.0682% | $1.56 | $46,710 | +1.27% | |||
| 2022-09-16 | director | 13,000 0.0296% | $1.56 | $20,233 | +1.27% | |||
| 2022-09-15 | director | 150,000 0.3544% | $1.71 | $256,500 | -4.49% | |||
| 2022-09-15 | director | 10,000 0.0237% | $1.72 | $17,168 | -4.49% | |||
| 2021-09-21 | director | 30,000 0.0764% | $6.75 | $202,500 | -58.36% | |||
| 2021-09-10 | Chief Financial Officer | 30,000 0.0779% | $6.47 | $194,000 | -54.92% | |||
| 2021-03-26 | director | 2,900 0.0081% | $10.32 | $29,933 | -37.55% | |||
| 2021-03-23 | director | 10,000 0.0273% | $10.23 | $102,300 | -37.74% | |||
| 2021-03-23 | director | 2,370 0.0066% | $10.42 | $24,689 | -37.74% | |||
| 2021-03-23 | Chief Executive Officer | 965 0.0027% | $10.34 | $9,980 | -37.74% | |||
| 2021-03-23 | Exec. VP and COO | 960 0.0026% | $10.31 | $9,898 | -37.74% | |||
| 2021-03-22 | director | 3,000 0.0083% | $10.95 | $32,850 | -40.92% |
Insider Historical Profitability
| PACE GARY W | director | 1059376 1.5926% | $3.92 | 9 | 0 | +78.54% |
| Levine James E. | Chief Financial Officer | 67716 0.1018% | $3.92 | 5 | 0 | <0.0001% |
| TANNENBAUM RENEE P | director | 20000 0.0301% | $3.92 | 2 | 0 | <0.0001% |
| Hunter Robert Merrill | 10 percent owner | 5065004 7.6144% | $3.92 | 1 | 0 | |
| BRIDGER MANAGEMENT, LLC | 2968115 4.4621% | $3.92 | 7 | 0 | <0.0001% |
Institutional Investor Ownership
| The Vanguard Group | $10.26M | 4.3 | 1.92M | +0.49% | +$50,559.12 | <0.0001 | |
| Laurion Capital Management LP | $4.96M | 2.08 | 928,717 | +28.61% | +$1.1M | 0.04 | |
| Millennium Management LLC | $3.65M | 1.53 | 683,299 | New | +$3.65M | <0.01 | |
| BlackRock | $3.62M | 1.52 | 677,458 | -5.45% | -$208,430.90 | <0.0001 | |
| MAI Capital Management, LLC | $2.94M | 1.23 | 551,124 | +45.3% | +$917,486.71 | 0.03 |